Luke Evnin, PhD

Co-Founder & Senior Advisor

Luke is one of the most successful and impactful venture capitalists in the life sciences industry.

Luke co-founded MPM Capital (the predecessor to MPM BioImpact) in 1997, and over the course of the past twenty-five years, MPM has founded and/or invested in more than one hundred companies and helped bring more than fifty therapeutics through regulatory approval. Amongst his accomplishments Luke has served on over thirty boards including nine public companies. Over the past decade, Luke has been a co-founder of seven companies.

Luke was co-founder and Chair of Co-Stim, a pioneering immuno-oncology company, which was acquired by Novartis; he was also co-founder and Chair of Maverick, also an immune-oncology company acquired by Takeda.

Luke stepped down from his full-time role at MPM in 2023 to put additional focus on his multi-decade involvement with the Scleroderma Research Foundation. Luke has chaired the board of the Scleroderma Research Foundation since 2002, and he assumed the role of Co-Director of Research in 2022.

Venture capital: Three+ decades
Accel, MPM

Co-Founder & Managing
Director,
1997-2023
Senior Advisor, present

Chairman
1999-Current

Follow Luke

on LinkedIn